Agilent - Breakthroughs in Immunotherapy- 2019 - 21

Application Note

Immunophenotyping,
Above and Beyond
Targeting the immune system has dramatically increased
the need for tracking the native and more recently
engineered phenotypes of multiple cell lineages.

F

low cytometry has developed from being a quantitative tool for identifying and classifying
mixtures of cells using fluorochrome-labeled monoclonal antibodies, to becoming an essential
workhorse for cell analysis research and development. The last decade has brought a series
of advancements in instrumentation and software along with an exponential expansion of antibodies
and fluorochromes. This has dramatically expanded the applications and cell phenotypes that can be
accurately measured with the blink of an eye1. It is no longer a characterization tool but a comprehensive phenotyping system with blazing speed and a growing rainbow of fluorophores to maximize the
number of parameters that can be measured per cell.

In human testing, cytometric immunophenotyping is now employed routinely to diagnose, classify,
stage and monitor therapy in blood cancers and a growing list of age-related diseases.2 It can be used
to determine the origin and stage of differentiation of leukemias and lymphomas.3 Sampling is nominally invasive, making it an ideal method for monitoring treatment and detecting recurrence, especially
in cell-based immunotherapies.4
The deep roots and recent successes of immunotherapy in cancer treatment is rapidly changing the
21

| GENengnews.com

Additional Info

Read this
Novocyte
Quanteon
application note
to learn more:


https://go.aceabio.com/l/492941/2018-10-22/n91jyq/492941/142853/NC_App_Note_21_Comprehensive_18_color_pan.pdf http://www.GENengnews.com

Agilent - Breakthroughs in Immunotherapy- 2019

Table of Contents for the Digital Edition of Agilent - Breakthroughs in Immunotherapy- 2019

Contents
Agilent - Breakthroughs in Immunotherapy- 2019 - 1
Agilent - Breakthroughs in Immunotherapy- 2019 - 2
Agilent - Breakthroughs in Immunotherapy- 2019 - 3
Agilent - Breakthroughs in Immunotherapy- 2019 - Contents
Agilent - Breakthroughs in Immunotherapy- 2019 - 5
Agilent - Breakthroughs in Immunotherapy- 2019 - 6
Agilent - Breakthroughs in Immunotherapy- 2019 - 7
Agilent - Breakthroughs in Immunotherapy- 2019 - 8
Agilent - Breakthroughs in Immunotherapy- 2019 - 9
Agilent - Breakthroughs in Immunotherapy- 2019 - 10
Agilent - Breakthroughs in Immunotherapy- 2019 - 11
Agilent - Breakthroughs in Immunotherapy- 2019 - 12
Agilent - Breakthroughs in Immunotherapy- 2019 - 13
Agilent - Breakthroughs in Immunotherapy- 2019 - 14
Agilent - Breakthroughs in Immunotherapy- 2019 - 15
Agilent - Breakthroughs in Immunotherapy- 2019 - 16
Agilent - Breakthroughs in Immunotherapy- 2019 - 17
Agilent - Breakthroughs in Immunotherapy- 2019 - 18
Agilent - Breakthroughs in Immunotherapy- 2019 - 19
Agilent - Breakthroughs in Immunotherapy- 2019 - 20
Agilent - Breakthroughs in Immunotherapy- 2019 - 21
Agilent - Breakthroughs in Immunotherapy- 2019 - 22
Agilent - Breakthroughs in Immunotherapy- 2019 - 23
Agilent - Breakthroughs in Immunotherapy- 2019 - 24
Agilent - Breakthroughs in Immunotherapy- 2019 - 25
Agilent - Breakthroughs in Immunotherapy- 2019 - 26
Agilent - Breakthroughs in Immunotherapy- 2019 - 27
Agilent - Breakthroughs in Immunotherapy- 2019 - 28
Agilent - Breakthroughs in Immunotherapy- 2019 - 29
Agilent - Breakthroughs in Immunotherapy- 2019 - 30
Agilent - Breakthroughs in Immunotherapy- 2019 - 31
Agilent - Breakthroughs in Immunotherapy- 2019 - 32
Agilent - Breakthroughs in Immunotherapy- 2019 - 33
Agilent - Breakthroughs in Immunotherapy- 2019 - 34
Agilent - Breakthroughs in Immunotherapy- 2019 - 35
Agilent - Breakthroughs in Immunotherapy- 2019 - 36
Agilent - Breakthroughs in Immunotherapy- 2019 - 37
Agilent - Breakthroughs in Immunotherapy- 2019 - 38
Agilent - Breakthroughs in Immunotherapy- 2019 - 39
https://www.nxtbookmedia.com